

World Journal of *Gastrointestinal Surgery*

World J Gastrointest Surg 2023 August 27; 15(8): 1559-1840



MINIREVIEWS

- 1559 Impact of tumour rupture risk on the oncological rationale for the surgical treatment choice of gastrointestinal stromal tumours
Peparini N
- 1564 Prevention and treatment of hepatic encephalopathy during the perioperative period of transjugular intrahepatic portosystemic shunt
Wang LJ, Yao X, Qi Q, Qin JP
- 1574 Vascular complications of chronic pancreatitis and its management
Walia D, Saraya A, Gunjan D
- 1591 Historical changes in surgical strategy and complication management for hepatic cystic echinococcosis
A JD, Chai JP, Jia SL, A XR

ORIGINAL ARTICLE

Basic Study

- 1600 High spindle and kinetochore-associated complex subunit-3 expression predicts poor prognosis and correlates with adverse immune infiltration in hepatocellular carcinoma
Zheng LL, Wang YR, Liu ZR, Wang ZH, Tao CC, Xiao YG, Zhang K, Wu AK, Li HY, Wu JX, Xiao T, Rong WQ

Case Control Study

- 1615 Post-transplant biliary complications using liver grafts from deceased donors older than 70 years: Retrospective case-control study
Jimenez-Romero C, Justo-Alonso I, del Pozo-Elso P, Marcacuzco-Quinto A, Martín-Arriscado-Arroba C, Manrique-Municio A, Calvo-Pulido J, García-Sesma A, San Román R, Caso-Maestro O
- 1629 Goldilocks principle of minimally invasive surgery for gastric subepithelial tumors
Chang WJ, Tsao LC, Yen HH, Yang CW, Chang HC, Kor CT, Wu SC, Lin KH

Retrospective Cohort Study

- 1641 Prognosis after splenectomy plus pericardial devascularization *vs* transjugular intrahepatic portosystemic shunt for esophagogastric variceal bleeding
Qi WL, Wen J, Wen TF, Peng W, Zhang XY, Shen JY, Li X, Li C
- 1652 Initial suction drainage decreases severe postoperative complications after pancreatic trauma: A cohort study
Li KW, Wang K, Hu YP, Yang C, Deng YX, Wang XY, Liu YX, Li WQ, Ding WW

Retrospective Study

- 1663** Radiation therapy prior to a pancreaticoduodenectomy for adenocarcinoma is associated with longer operative times and higher blood loss
Aploks K, Kim M, Stroever S, Ostapenko A, Sim YB, Sooriyakumar A, Rahimi-Ardabili A, Seshadri R, Dong XD
- 1673** Prognostic significance of preoperative lymphocyte to monocyte ratio in patients with signet ring gastric cancer
Liu HL, Feng X, Tang MM, Zhou HY, Peng H, Ge J, Liu T
- 1684** Clinical efficacy of total laparoscopic splenectomy for portal hypertension and its influence on hepatic hemodynamics and liver function
Qi RZ, Li ZW, Chang ZY, Chang WH, Zhao WL, Pang C, Zhang Y, Hu XL, Liang F
- 1693** Accurate resection of hilar cholangiocarcinoma using eOrganmap 3D reconstruction and full quantization technique
Cui DP, Fan S, Guo YX, Zhao QW, Qiao YX, Fei JD
- 1703** Regional differences in islet amyloid deposition in the residual pancreas with new-onset diabetes secondary to pancreatic ductal adenocarcinoma
Wang R, Liu Y, Liang Y, Zhou L, Chen MJ, Liu XB, Tan CL, Chen YH
- 1712** Risk factors and their interactive effects on severe acute pancreatitis complicated with acute gastrointestinal injury
Chen JH, Zhang MF, Du WC, Zhang YA
- 1719** Effects of ultrasound monitoring of gastric residual volume on feeding complications, caloric intake and prognosis of patients with severe mechanical ventilation
Xu XY, Xue HP, Yuan MJ, Jin YR, Huang CX
- 1728** Enhanced recovery nursing and mental health education on postoperative recovery and mental health of laparoscopic liver resection
Li DX, Ye W, Yang YL, Zhang L, Qian XJ, Jiang PH
- 1739** Changing trends in gastric and colorectal cancer among surgical patients over 85 years old: A multicenter retrospective study, 2001–2021
Chen K, Li M, Xu R, Zheng PP, Chen MD, Zhu L, Wang WB, Wang ZG

Observational Study

- 1751** Knowledge, attitude, and practice of monitoring early gastric cancer after endoscopic submucosal dissection
Yang XY, Wang C, Hong YP, Zhu TT, Qian LJ, Hu YB, Teng LH, Ding J
- 1761** Anti-reflux effects of a novel esophagogastric asymmetric anastomosis technique after laparoscopic proximal gastrectomy
Pang LQ, Zhang J, Shi F, Pang C, Zhang CW, Liu YL, Zhao Y, Qian Y, Li XW, Kong D, Wu SN, Zhou JF, Xie CX, Chen S
- 1774** Prognostic scores in primary biliary cholangitis patients with advanced disease
Feng J, Xu JM, Fu HY, Xie N, Bao WM, Tang YM

SYSTEMATIC REVIEWS

- 1784** Maternal choledochal cysts in pregnancy: A systematic review of case reports and case series
Augustin G, Romic I, Miličić I, Mikuš M, Herman M
- 1799** Intraoperative pancreas stump perfusion assessment during pancreaticoduodenectomy: A systematic scoping review
Robertson FP, Spiers HVM, Lim WB, Loveday B, Roberts K, Pandanaboyana S
- 1808** Comparison between upfront surgery and neoadjuvant chemotherapy in patients with locally advanced gastric cancer: A systematic review
Fiflis S, Papakonstantinou M, Giakoustidis A, Christodoulidis G, Louri E, Papadopoulos VN, Giakoustidis D

CASE REPORT

- 1819** Long-term survival of patients with hepatocellular carcinoma with hepatic, pulmonary, peritoneal and rare colon metastasis: A case report
Gong YQ, Lu TL, Chen CW
- 1825** Donor hepatic artery reconstruction based on human embryology: A case report
Zhang HZ, Lu JH, Shi ZY, Guo YR, Shao WH, Meng FX, Zhang R, Zhang AH, Xu J
- 1831** Outpatient hybrid endoscopic submucosal dissection with SOUTEN for early gastric cancer, followed by endoscopic suturing of the mucosal defect: A case report
Ito R, Miwa K, Matano Y

LETTER TO THE EDITOR

- 1838** Is endoscopic mucosal resection-precutting superior to conventional methods for removing sessile colorectal polyps?
Yang QY, Zhao Q, Hu JW

ABOUT COVER

Editorial Board Member of *World Journal of Gastrointestinal Surgery*, Raja Kalayarasan, MS, DNB, MCh, FRCS (Ed), Additional Professor & Head, Department of Surgical Gastroenterology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry 605006, India. kalayarasanraja@yahoo.com

AIMS AND SCOPE

The primary aim of *World Journal of Gastrointestinal Surgery* (WJGS, *World J Gastrointest Surg*) is to provide scholars and readers from various fields of gastrointestinal surgery with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGS mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal surgery and covering a wide range of topics including biliary tract surgical procedures, biliopancreatic diversion, colectomy, esophagectomy, esophagostomy, pancreas transplantation, and pancreatectomy, etc.

INDEXING/ABSTRACTING

The WJGS is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJGS as 2.0; IF without journal self cites: 1.9; 5-year IF: 2.2; Journal Citation Indicator: 0.52; Ranking: 113 among 212 journals in surgery; Quartile category: Q3; Ranking: 81 among 93 journals in gastroenterology and hepatology; and Quartile category: Q4.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Rui-Rui Wu; Production Department Director: Xiang Li; Editorial Office Director: Jia-Ru Fan.

NAME OF JOURNAL

World Journal of Gastrointestinal Surgery

ISSN

ISSN 1948-9366 (online)

LAUNCH DATE

November 30, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Peter Schemmer

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/1948-9366/editorialboard.htm>

PUBLICATION DATE

August 27, 2023

COPYRIGHT

© 2023 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Impact of tumour rupture risk on the oncological rationale for the surgical treatment choice of gastrointestinal stromal tumours

Nadia Peparini

Specialty type: Surgery

Provenance and peer review:

Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B, B
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Imai Y, Japan; Samara AA, Greece

Received: December 23, 2022

Peer-review started: December 23, 2022

First decision: January 9, 2023

Revised: January 25, 2023

Accepted: June 19, 2023

Article in press: June 19, 2023

Published online: August 27, 2023



Nadia Peparini, Azienda Sanitaria Locale Roma 6, Ciampino, Rome 00043, Italy

Corresponding author: Nadia Peparini, MD, PhD, Azienda Sanitaria Locale Roma 6, Distretto 3, Via Mario Calò 5, Ciampino, Rome 00043, Italy. nadiapeparini@yahoo.it

Abstract

Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.

Key Words: Gastrointestinal stromal tumours; Tumour rupture; Residual tumour; Resection margin; Prognostic factors; Surgical treatment

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Tumour rupture is a remarkable risk factor that can change the natural history of low-risk gastrointestinal stromal tumours (GISTs) to a high-risk GIST. This review analyses the concept and prognostic value of tumour rupture in GISTs and highlights the impact of the risk of tumour rupture on the choice of surgical strategy.

Citation: Peparini N. Impact of tumour rupture risk on the oncological rationale for the surgical treatment choice of gastrointestinal stromal tumours. *World J Gastrointest Surg* 2023; 15(8): 1559-1563

URL: <https://www.wjgnet.com/1948-9366/full/v15/i8/1559.htm>

DOI: <https://dx.doi.org/10.4240/wjgs.v15.i8.1559>

INTRODUCTION

Tumour rupture in gastrointestinal stromal tumours (GISTs) has not been consistently defined in published studies. Although many studies have found an increased risk of recurrence and lower survival rates in patients with tumour rupture, other studies have not found any unfavourable prognostic effect. This is likely due to differences in tumour rupture definitions[1]. Tumour rupture has been considered to be a remarkable (often surgery-related) risk factor that can change the natural history of a low-risk GIST to a high-risk GIST, heavily impacting the long-term outcome[2-5]. However, in addition to tumour rupture, different factors may also impact GIST prognosis. Synchronous GISTs and another primary tumour can significantly increase in the possibility for recurrent disease, resulting in a worse prognosis and a more aggressive course than a single GIST[6].

This review analyses the concept of tumour rupture and its prognostic value in GISTs and highlights the impact of the risk of tumour rupture during surgical treatment for these tumours. Additionally, it emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.

THE CONCEPT OF TUMOUR RUPTURE IN GISTS

Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. According to these new definitions, the constant factor of all major defects of tumour integrity that qualify for tumour rupture (*i.e.*, tumour fracture and/or tumour spillage in the abdominal cavity, blood-stained ascites, gastrointestinal perforation at the tumour site, microscopic transperitoneal adjacent organ infiltration, piecemeal resection or intralesional dissection, and incisional biopsy)[7,8] is substantial peritoneal exposure to tumour cells. This should be considered a remarkable risk factor because of potential peritoneal contamination. In contrast, minor defects of tumour integrity (such as those caused by core needle biopsy, microscopic peritoneal tumour penetration, iatrogenic superficial tumour capsule laceration or microscopically positive margins) are not considered tumour rupture [7-9].

THE IMPACT OF TUMOUR RUPTURE ON THE PROGNOSIS OF RESECTED GISTS

The impact of R1 resection on the oncological outcome of resectable gastrointestinal stromal tumours is debated. A systematic review and meta-analysis indicated that a microscopically positive margin could significantly impact disease-free survival but had no influence on overall survival. Moreover, adjuvant imatinib treatment could reduce the risk of recurrence for R1 resected primary GISTs[10].

Rutkowski *et al*[11] noted that GIST is a tumour growing under the mucosa and may be often ulcerated. Consequently, the mucosal margin from the gastrointestinal lumen is not clinically meaningful. The authors indicated that the margins of clinical importance that are relevant to assess R status (*i.e.*, R0, R1 or R2) are the peritoneal cavity side, which disruption entails tumour rupture, lateral margins or proximal and distal resection margins of the stomach/intestine wall, whose excision should be verified[11].

However, regarding the residual tumour classification of GISTs, it should be considered that not all tumour ruptures are classified as R1 or R2 resection. Nishida highlighted that peritoneum involvement is unrelated to R status; thus, a GIST disrupted in terms of peritoneal penetration otherwise resected with negative margins is still considered an R0 resection[8].

In their systematic review and meta-analysis, Kong *et al*[12] analysed the impact of R1 resection on the survival outcome of resectable GISTs with and without tumour rupture. They found that when tumour rupture cases were included, R1 resection resulted in a significantly shorter recurrence-free survival or disease-free survival than R0 resection, but the differences in recurrence-free survival and disease-free survival between R0 and R1 resection vanished when tumour rupture cases were excluded[12]. The results of most recent studies suggest that R1 resection does not influence the oncological outcome of resectable GIST compared with R0 resection; consequently, resection may not be necessary when a positive microscopic margin exists. Moreover, R1 resection would not be considered an indication for adjuvant imatinib treatment in the absence of other high-risk factors as well as tumour rupture[12-17]. However, tumour rupture is significantly associated with the occurrence of R1 resection[12]. Mc Carter and colleagues noted that the significant risk factors associated with a positive microscopic resection margin are tumour size ≥ 10 cm, location and intraperitoneal rupture, and found that the risk of disease recurrence in R1 patients was driven largely by the presence of tumour rupture[18].

TUMOR-NODE-METASTASIS CLASSIFICATION OF GISTS

In the tumor-node-metastasis (TNM) classification of GISTs T (tumour) staging is dependent on the size of the tumour (T1: ≤ 2 cm; T2: > 2 cm and ≤ 5 cm; T3: > 5 and ≤ 10 cm; T4: > 10 cm) and not on the depth of local invasion. TNM staging is dependent on the site (gastric and omental GISTs have a better prognosis than small bowel GISTs or other less common intestinal GISTs), size (T), regional lymph node (N) status and mitotic rate (low mitotic rate: 5 or fewer per 50 high power fields; high mitotic rate: over 5 per 50 high power fields).

In contrast to the TNM classification of gastrointestinal carcinomas, in the TNM classification of GISTs: (1) Involvement of the peritoneum is not prognostically graded as an unfavourable T (tumour) factor, *i.e.*, T4a; and (2) after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Moreover, tumour rupture, which may be the true unfavourable prognostic factor instead of R1, has not yet been included in the current TNM Classification of GISTs[19]. From a prognostic point of view macroscopic injuries to the pseudocapsule (which are considered tumour rupture) should be distinguished from microscopic breaks of the pseudocapsule on pathological examination (that are not considered to be tumour rupture)[20]. However, the choice of surgical strategy should consider the unfavourable impact of an eventual tumour rupture on prognosis and the risk of tumour rupture when performing a dissection on the tumour surface (pseudocapsule), *i.e.*, without clearance distance[21].

OPTIONS IN THE SURGICAL TREATMENT OF GISTS

Everett and colleagues emphasised that tumour enucleation is considered insufficient because it may leave behind a tumour-seeded pseudocapsule. Moreover, enucleation is associated with tumour rupture[22] and should not be performed even if it is useful to preserve a vital structure. Interruption of the pseudocapsule or incidental peritumoral disruption can change a curable disease to a poor prognostic tumour. Accurate handling is very important to avoid tumour rupture because GISTs are soft and fragile. This can be a problem in laparoscopic and endoscopic treatment of GIST because of the instrumental manipulation of the tumours. Small low-grade GISTs are often treated by endoscopic resection. However, Song and colleagues argued that in the case of smaller tumours (median tumour size of all patients in their study was 1.5 cm; range 0.3-5 cm), the predictive value of tumour rupture and mitotic index diminished, and the risk of peritoneal metastasis may not be increased, even in tumours ruptured during endoscopic resection[23]. Due to the risks of tumour rupture, tumour remnants, perforation and bleeding, endoscopic resection is not currently recommended as a routine treatment for GISTs of the upper or lower gastrointestinal tract. However, it might be comparable to surgical resection for selected smaller tumours (< 3 cm in size). Surgical resection is still considered the standard treatment for tumours ≥ 2 cm or if the tumour has a high mitotic index or mucosal ulceration[24]. However, a high mitotic index is mostly unknown before resection.

According to the most recent guidelines, the standard treatment for localized GISTs is complete surgical excision of the lesion, with no dissection of clinically negative lymph nodes. The goal is R0 excision, *i.e.*, an excision whose margins are clear of tumour cells at least at the site of origin in the GI tract. In low-risk GISTs located in unfavourable locations, R1 margins can be acceptable, given the lack of evidence that R1 surgery is associated with a worse overall survival.

A laparoscopic/robotic approach is clearly discouraged in patients who have large tumours because of the risk of tumour rupture, which is associated with a very high risk of relapse. For selected patients with small tumours in the upper or lower GI tract, endoscopic excision is an acceptable treatment strategy[25]. Three years of adjuvant imatinib is the standard treatment for resected ruptured GISTs, although the recurrence rate is prominently high[26], and five years of adjuvant imatinib treatment in patients with ruptured GISTs seems to be promising[27,28].

CONCLUSION

In the choice of a surgical strategy for GISTs, key points should be considered. First, R1 resection cannot be a standard treatment for GISTs, and second, the risk of tumour rupture should be carefully evaluated and avoided. According to these key points: (1) Enucleation cannot be considered a standard treatment for GISTs localized in favourable resection sites; (2) laparoscopic/robotic excisions cannot be the standard treatments for large GISTs; and (3) endoscopic treatment cannot be considered a routine procedure for smaller GISTs (Figure 1).




Figure 1 Surgical strategies for gastrointestinal stromal tumours according to key points. GISTs: Gastrointestinal stromal tumours.

FOOTNOTES

Author contributions: Peparini N conceived and performed research, analyzed data, wrote and revised the manuscript and gave the final approval.

Conflict-of-interest statement: The author reported no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/Licenses/by-nc/4.0/>

Country/Territory of origin: Italy

ORCID number: Nadia Peparini 0000-0002-4455-3489.

S-Editor: Gong ZM

L-Editor: A

P-Editor: Wu RR

REFERENCES

- Asare EA, Feig BW. Raining Frogs, Flying Horses, and Defining Tumor Rupture in GIST. *Ann Surg Oncol* 2019; **26**: 1601-1603 [PMID: 30903324 DOI: 10.1245/s10434-019-07307-w]
- Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. *Hum Pathol* 2008; **39**: 1411-1419 [PMID: 18774375 DOI: 10.1016/j.humpath.2008.06.025]
- Rutkowski P, Bylina E, Wozniak A, Nowecki ZI, Osuch C, Matlok M, Switaj T, Michej W, Wroński M, Głuszek S, Kroc J, Nasierowska-Guttmejer A, Joensuu H. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes. *Eur J Surg Oncol* 2011; **37**: 890-896 [PMID: 21737227 DOI: 10.1016/j.ejso.2011.06.005]
- Qu H, Xu Z, Ren Y, Gong Z, Ju RH, Zhang F, Shao S, Chen X. The analysis of prognostic factors of primary small intestinal gastrointestinal stromal tumors with R0 resection: A single-center retrospective study. *Medicine (Baltimore)* 2022; **101**: e29487 [PMID: 35758385 DOI: 10.1097/MD.00000000000029487]
- Holmebakk T, Wiedswang AM, Meza-Zepeda LA, Hompland I, Lobmaier IVK, Berner JM, Stoldt S, Boye K. Integrating Anatomical, Molecular and Clinical Risk Factors in Gastrointestinal Stromal Tumor of the Stomach. *Ann Surg Oncol* 2021; **28**: 6837-6845 [PMID: 33651216 DOI: 10.1245/s10434-021-09605-8]
- Diamantis A, Samara AA, Symeonidis D, Baloyiannis I, Vasdeki D, Tolia M, Volakakis G, Mavrounias G, Tepetes K. Gastrointestinal stromal tumors (GISTs) and synchronous intra-abdominal malignancies: case series of a single institution's experience. *Oncotarget* 2020; **11**: 4813-4821 [PMID: 33447349 DOI: 10.18632/oncotarget.27853]
- Holmebakk T, Bjerkehaugen B, Boye K, Bruland Ø, Stoldt S, Sundby Hall K. Definition and clinical significance of tumour rupture in gastrointestinal stromal tumours of the small intestine. *Br J Surg* 2016; **103**: 684-691 [PMID: 26988241 DOI: 10.1002/bjs.10104]
- Nishida T, Holmebakk T, Raut CP, Rutkowski P. Defining Tumor Rupture in Gastrointestinal Stromal Tumor. *Ann Surg Oncol* 2019; **26**: 1669-1675 [PMID: 30868512 DOI: 10.1245/s10434-019-07297-9]

- 9 **Casali PG**, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brodowicz T, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dufresne A, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Frezza AM, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Haas R, Hassan AB, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kasper B, Kawai A, Kopeckova K, Krákorová DA, Le Cesne A, Le Grange F, Legius E, Leithner A, Lopez-Pousa A, Martin-Broto J, Merimsky O, Messiou C, Miah AB, Mir O, Montemurro M, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno-Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schöffski P, Sleijfer S, Strauss D, Strauss SJ, Hall KS, Trama A, Unk M, van de Sande MAJ, van der Graaf WTA, van Houdt WJ, Frebourg T, Gronchi A, Stacchiotti S; ESMO Guidelines Committee, EURACAN and GENTURIS. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2022; **33**: 20-33 [PMID: [34560242](#) DOI: [10.1016/j.annonc.2021.09.005](#)]
- 10 **Zhi X**, Jiang B, Yu J, Røe OD, Qin J, Ni Q, Sun L, Xu M, Zhu J, Ma L. Prognostic role of microscopically positive margins for primary gastrointestinal stromal tumors: a systematic review and meta-analysis. *Sci Rep* 2016; **6**: 21541 [PMID: [26891953](#) DOI: [10.1038/srep21541](#)]
- 11 **Rutkowski P**, Skoczylas J, Wisniewski P. Is the Surgical Margin in Gastrointestinal Stromal Tumors Different? *Visc Med* 2018; **34**: 347-352 [PMID: [30498701](#) DOI: [10.1159/000491649](#)]
- 12 **Kong M**, Liu G, Zhuo H, Xin Y, Chen H, Sheng H, Li L. Association between R1 resection and oncological outcome in resectable gastrointestinal stromal tumors without tumor rupture: A systematic review and meta-analysis. *Eur J Surg Oncol* 2021; **47**: 1526-1534 [PMID: [33573855](#) DOI: [10.1016/j.ejso.2021.01.032](#)]
- 13 **Pantuso G**, Macaione I, Taverna A, Guercio G, Incorvaia L, Di Piazza M, Di Grado F, Cilluffo G, Badalamenti G, Cipolla C. Surgical treatment of primary gastrointestinal stromal tumors (GISTs): Management and prognostic role of R1 resections. *Am J Surg* 2020; **220**: 359-364 [PMID: [31862107](#) DOI: [10.1016/j.amjsurg.2019.12.006](#)]
- 14 **Shannon AB**, Song Y, Fraker DL, Roses RE, DeMatteo RP, Miura JT, Karakousis GC. Do microscopic surgical margins matter for primary gastric gastrointestinal stromal tumor? *Surgery* 2021; **169**: 419-425 [PMID: [32863011](#) DOI: [10.1016/j.surg.2020.07.018](#)]
- 15 **Patel DJ**, Kulshrestha S, Bunn C, Littau M, Agnew S, Baker MS. Positive microscopic surgical margins: Is there an association with survival in resected small gastrointestinal stromal tumors? *Am J Surg* 2021; **221**: 549-553 [PMID: [33371951](#) DOI: [10.1016/j.amjsurg.2020.12.038](#)]
- 16 **Holmebakk T**, Bjerkehaugen B, Hompland I, Stoldt S, Boye K. Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour. *Br J Surg* 2019; **106**: 419-426 [PMID: [30507040](#) DOI: [10.1002/bjs.11027](#)]
- 17 **Holmebakk T**, Hompland I, Bjerkehaugen B, Stoldt S, Bruland ØS, Hall KS, Boye K. Recurrence-Free Survival After Resection of Gastric Gastrointestinal Stromal Tumors Classified According to a Strict Definition of Tumor Rupture: A Population-Based Study. *Ann Surg Oncol* 2018; **25**: 1133-1139 [PMID: [29435684](#) DOI: [10.1245/s10434-018-6353-5](#)]
- 18 **McCarter MD**, Antonescu CR, Ballman KV, Maki RG, Pisters PW, Demetri GD, Blanke CD, von Mehren M, Brennan MF, McCall L, Ota DM, DeMatteo RP; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant Gist Study Team. Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. *J Am Coll Surg* 2012; **215**: 53-9; discussion 59 [PMID: [22726733](#) DOI: [10.1016/j.jamcollsurg.2012.05.008](#)]
- 19 **Brierley JD**, Gospodarowicz MK, Wittekind C, eds. TNM Classification of Malignant Tumours. 8th edition. Oxford: John Wiley & Sons, Inc., 2017
- 20 **Nishida T**, Cho H, Hirota S, Masuzawa T, Chiguchi G, Tsujinaka T; Kinki GIST Study Group. Clinicopathological Features and Prognosis of Primary GISTs with Tumor Rupture in the Real World. *Ann Surg Oncol* 2018; **25**: 1961-1969 [PMID: [29752602](#) DOI: [10.1245/s10434-018-6505-7](#)]
- 21 **Peparini N**, Chirletti P. Tumor rupture during surgery for gastrointestinal stromal tumors: pay attention! *World J Gastroenterol* 2013; **19**: 2009-2010 [PMID: [23569350](#) DOI: [10.3748/wjg.v19.i12.2009](#)]
- 22 **Everett M**, Gutman H. Surgical management of gastrointestinal stromal tumors: analysis of outcome with respect to surgical margins and technique. *J Surg Oncol* 2008; **98**: 588-593 [PMID: [19072850](#) DOI: [10.1002/jso.21030](#)]
- 23 **Song S**, Ren W, Wang Y, Zhang S, Liu F, Cai Q, Xu G, Zou X, Wang L. Tumor rupture of gastric gastrointestinal stromal tumors during endoscopic resection: a risk factor for peritoneal metastasis? *Endosc Int Open* 2018; **6**: E950-E956 [PMID: [30083583](#) DOI: [10.1055/a-0619-4803](#)]
- 24 **Wu H**, Li H, Xu Q, Shang L, Zhang R, Li C, Fu M, Xu W, Chen J, Liu J, Li L. Surgical Resection Is Still Better Than Endoscopic Resection for Patients With 2-5 cm Gastric Gastrointestinal Stromal Tumours: A Propensity Score Matching Analysis. *Front Oncol* 2021; **11**: 737885 [PMID: [34604080](#) DOI: [10.3389/fonc.2021.737885](#)]
- 25 **Zhu H**, Zhao S, Jiao R, Zhou J, Zhang C, Miao L. Comparison of endoscopic versus laparoscopic resection for gastric gastrointestinal stromal tumors: A preliminary meta-analysis. *J Gastroenterol Hepatol* 2020; **35**: 1858-1868 [PMID: [32428968](#) DOI: [10.1111/jgh.15106](#)]
- 26 **Bang YH**, Ryu MH, Kim HD, Lee HE, Kang YK. Clinical outcomes and prognostic factors for patients with high-risk gastrointestinal stromal tumors treated with 3-year adjuvant imatinib. *Int J Cancer* 2022; **151**: 1770-1777 [PMID: [35678337](#) DOI: [10.1002/ijc.34157](#)]
- 27 **Kang S**, Ryu MH, Bang YH, Kim HD, Lee HE, Kang YK. Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis. *Cancer Res Treat* 2022; **54**: 1167-1174 [PMID: [34883555](#) DOI: [10.4143/crt.2021.1040](#)]
- 28 **Liu R**, Wu Y, Gong J, Zhao R, Li L, Wan Q, Lian N, Shen X, Xia L, Shen Y, Xiao H, Wu X, Chen Y, Cen Y, Xu X. Development and external validation of a nomogram for individualized adjuvant imatinib duration for high-risk gastrointestinal stromal tumors: A multicenter retrospective cohort study. *Cancer Med* 2022; **11**: 3093-3105 [PMID: [35297216](#) DOI: [10.1002/cam4.4673](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

